TransMedics Group (NASDAQ:TMDX) Rating Increased to Strong-Buy at Baird R W

TransMedics Group (NASDAQ:TMDX) was upgraded by stock analysts at Baird R W to a “strong-buy” rating in a research report issued on Tuesday, Zacks.com reports.

Other equities research analysts also recently issued research reports about the stock. Robert W. Baird assumed coverage on shares of TransMedics Group in a research report on Tuesday. They issued an “outperform” rating and a $200.00 target price for the company. Stephens increased their target price on TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. TD Cowen upped their price target on shares of TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, June 7th. Cantor Fitzgerald assumed coverage on shares of TransMedics Group in a report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective on the stock. Finally, Needham & Company LLC initiated coverage on shares of TransMedics Group in a report on Wednesday, August 21st. They set a “buy” rating and a $208.00 target price for the company. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, TransMedics Group presently has an average rating of “Buy” and an average price target of $174.30.

TransMedics Group Stock Performance

Shares of TMDX opened at $144.56 on Tuesday. The company has a market cap of $4.82 billion, a price-to-earnings ratio of -425.18 and a beta of 1.99. The business’s fifty day simple moving average is $156.02 and its two-hundred day simple moving average is $130.77. TransMedics Group has a 12 month low of $36.42 and a 12 month high of $177.37. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.21 by $0.14. The company had revenue of $114.30 million during the quarter, compared to the consensus estimate of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. TransMedics Group’s revenue for the quarter was up 117.7% on a year-over-year basis. During the same period last year, the company earned ($0.03) EPS. Research analysts anticipate that TransMedics Group will post 1.23 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In related news, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total value of $463,725.66. Following the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $3,267,557.11. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, Director James R. Tobin sold 20,000 shares of TransMedics Group stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $159.33, for a total value of $3,186,600.00. Following the sale, the director now directly owns 173,146 shares of the company’s stock, valued at $27,587,352.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total value of $463,725.66. Following the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at $3,267,557.11. The disclosure for this sale can be found here. Insiders sold a total of 61,247 shares of company stock valued at $9,650,880 over the last 90 days. Company insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Hedge funds have recently modified their holdings of the company. Fidelis Capital Partners LLC purchased a new stake in shares of TransMedics Group during the 1st quarter valued at about $35,000. International Assets Investment Management LLC purchased a new stake in TransMedics Group during the second quarter valued at approximately $47,000. J.Safra Asset Management Corp lifted its stake in shares of TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after purchasing an additional 383 shares during the last quarter. Signaturefd LLC boosted its holdings in shares of TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the period. Finally, Amalgamated Bank boosted its holdings in shares of TransMedics Group by 6.7% in the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after purchasing an additional 70 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.